Cardiff Oncology Inc (CRDF) News & EventsCRDFCardiff Oncology Inc

Cardiff Oncology Appoints Leila Alland as Interim Chief Medical Officer

Cardiff Oncology announced the appointment of Leila Alland as interim chief medical officer. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs. Alland succeeds Roger Sidhu, who has stepped down from his role as chief medical officer. "We are pleased to welcome Leila as interim Chief Medical Officer. She brings a strong track record of leadership in advancing novel cancer therapies and is well-positioned to guide our clinical strategy as we enter a pivotal phase in clinical development. Our randomized Phase 2 trial in first line RAS-mutated metastatic colorectal cancer is still ongoing, and median PFS has not been reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm, our proposed Phase 3 regimen. All patients remaining on trial have now been on treatment for more than 18 months. We are at a defining period for Cardiff as we prepare to initiate our registrational Phase 3 study in the first quarter of 2027. Leila's expertise will be instrumental as we advance this program and also evaluate the broader potential of PLK1 inhibition in other cancers with few treatment options," said Mani Mohindru, CEO.

Cardiff Oncology and Nerviano Reach Settlement

Cardiff Oncology and Nerviano Medical Sciences announced that they have reached a settlement and amended their 2017 exclusive license agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing an expanded collaborative framework to support onvansertib's continued clinical development. Cardiff and NMS have agreed to a full and mutual release of all claims asserted in the litigation pending in the U.S. District Court for the Southern District of California. Cardiff and NMS plan to jointly request dismissal of all claims with prejudice. The parties clarified and expanded on the royalty structure in the license agreement. The agreement also includes development objectives related to Cardiff's upcoming Phase 3 program, as well as rights for NMS to appoint a board observer and join Cardiff's scientific advisory board.